Related Experiment Videos
Desmoid tumours treated with triphenylethylenes
M D Brooks1, S R Ebbs, A A Colletta
1Mayday University Hospital, Croydon, U.K.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Summary
Tamoxifen and toremifene show promise in treating desmoid tumors, with 65% of patients experiencing disease stabilization or resolution. This suggests potential therapeutic benefits beyond anti-estrogenic effects in mesenchymal tumors.
Area of Science:
- Oncology
- Pharmacology
Background:
- Desmoid tumors are rare mesenchymal neoplasms.
- They can occur at multiple sites and are occasionally linked to polyposis coli.
Observation:
- This study evaluated tamoxifen and toremifene in 20 patients with progressive desmoid disease.
- Responses ranged from disease stabilization to complete resolution in 65% of patients.
Findings:
- The anti-tumor activity of tamoxifen and toremifene is often linked to anti-estrogenic properties.
- Desmoid tumors, as mesenchymal neoplasms, responded despite low hormone receptor levels.
Implications:
- This suggests that the stromal component of tumors may influence drug response, irrespective of hormone receptor status.
- These findings highlight the importance of tumor stroma in understanding therapeutic efficacy for mesenchymal tumors.